Frontlight ResearchEarly access
Active, not recruitingNo phase
Myocardial FIbrosis in Repaired Tetralogy of FAllot- FIFA Study)
Key facts
- Who runs it
- Hospital Universitari Vall d'Hebron Research Institute
- Where
- Spain7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 224 people, planned
- Started
- 9 Jul 2018
- Expected to end
- Dec 2026
- Type of study
- Observational
- Record updated
- 29 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Patients aged 18 years or older with repaired tetralogy of Fallot or double outlet right ventricle Fallot type
Who cannot take part
- Patients with pathologies that affect collagen metabolism (liver cirrhosis, stage ≥4 renal insufficiency, pulmonary fibrosis, metabolic bone disease, connective tissue diseases, active neoplasms, active treatment with corticosteroids and bone fractures or surgery in the previous 6 months)
- Patients with pathologies that may interfere with the determination of the extracellular volume of myocardium (ischemic heart disease, storage diseases)
- Pregnancy
- Denial of informed consent
- Patients with claustrophobia and pacemakers or defibrillators
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to study the correlation between biomarkers of myocardial fibrosis (extracellular volume fraction calculated by cardiac magnetic resonance imaging (MRI) (T1-mapping) and levels of molecular biomarkers of fibrosis) and adverse events in a population of patients with repaired tetralogy of Fallot.
The group in the trial
- Patients
Patients with Tetralogy of Fallot
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Interstitial Myocardial Fibrosis in Repaired Tetralogy of Fallot: Assessment by Molecular and Imaging Biomarkers and Association With Adverse Events ( Myocardial FIbrosis in Repaired Tetralogy of FAllot- FIFA Study)
- Record updated
- 29 April 2026